United therapeutics corporation UTHR.US Overview
UTHR AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
UTHR Current Performance
-1.49%
United therapeutics corporation
-1.83%
Avg of Sector
-0.40%
S&P500
UTHR Key Information
UTHR Revenue by Segments
Browsing restrictions can be lifted for a fee.
UTHR Net Income
Browsing restrictions can be lifted for a fee.
UTHR Cash Flow
Browsing restrictions can be lifted for a fee.
UTHR Profit Margin
Browsing restrictions can be lifted for a fee.
UTHR PE Ratio River
Browsing restrictions can be lifted for a fee.
UTHR Financial Forecast
Browsing restrictions can be lifted for a fee.
UTHR Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
UTHR Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Price of UTHR
UTHR FAQ
When is UTHR's latest earnings report released?
The most recent financial report for United therapeutics corporation (UTHR) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating UTHR's short-term business performance and financial health. For the latest updates on UTHR's earnings releases, visit this page regularly.
Where does UTHR fall in the P/E River chart?
According to historical valuation range analysis, United therapeutics corporation (UTHR)'s current price-to-earnings (P/E) ratio is 11.29, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of UTHR?
According to the latest financial report, United therapeutics corporation (UTHR) reported an Operating Profit of 382.8M with an Operating Margin of 48.19% this period, representing a growth of 7.44% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is UTHR's revenue growth?
In the latest financial report, United therapeutics corporation (UTHR) announced revenue of 794.4M, with a Year-Over-Year growth rate of 17.22%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does UTHR have?
At the end of the period, United therapeutics corporation (UTHR) held Total Cash and Cash Equivalents of 1.9B, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does UTHR go with three margins increasing?
In the latest report, United therapeutics corporation (UTHR) achieved the “three margins increasing” benchmark, with a gross margin of 88.4%%, operating margin of 48.19%%, and net margin of 40.6%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess UTHR's profit trajectory and future growth potential.
Is UTHR's EPS continuing to grow?
According to the past four quarterly reports, United therapeutics corporation (UTHR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 7.18. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of UTHR?
United therapeutics corporation (UTHR)'s Free Cash Flow (FCF) for the period is 386.3M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 14.19% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.